11/18
08:07 am
eras
Erasca, Inc. (NASDAQ: ERAS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
Medium
Report
Erasca, Inc. (NASDAQ: ERAS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
11/15
11:54 am
eras
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
Low
Report
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
11/13
08:05 am
eras
Erasca, Inc. (NASDAQ: ERAS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Erasca, Inc. (NASDAQ: ERAS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
11/12
04:01 pm
eras
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
Medium
Report
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
11/5
08:00 am
eras
Erasca to Present at Upcoming Investor Conferences
Low
Report
Erasca to Present at Upcoming Investor Conferences
10/25
12:34 pm
eras
Erasca, Inc. (NASDAQ: ERAS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $3.00 to $3.50. They now have a "buy" rating on the stock.
Medium
Report
Erasca, Inc. (NASDAQ: ERAS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $3.00 to $3.50. They now have a "buy" rating on the stock.
10/25
08:37 am
eras
Erasca, Inc. (NASDAQ: ERAS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Erasca, Inc. (NASDAQ: ERAS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/24
08:00 am
eras
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Medium
Report
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
9/30
12:31 pm
eras
Erasca: New Focus After Restructuring, But Need More Differentiation [Seeking Alpha]
Low
Report
Erasca: New Focus After Restructuring, But Need More Differentiation [Seeking Alpha]
9/25
08:00 am
eras
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Medium
Report
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
9/23
10:29 am
eras
Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company [Yahoo! Finance]
Medium
Report
Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company [Yahoo! Finance]
8/29
08:00 am
eras
Erasca to Present at Upcoming Investor Conferences in September
Low
Report
Erasca to Present at Upcoming Investor Conferences in September